Organon Dividends and Buybacks
Dividend criteria checks 2/6
Organon is a dividend paying company with a current yield of 0.89% that is well covered by earnings. Next payment date is on 12th June, 2025 with an ex-dividend date of 12th May, 2025.
Key information
0.9%
Dividend yield
0.9%
Buyback Yield
| Total Shareholder Yield | 1.8% |
| Future Dividend Yield | 0.9% |
| Dividend Growth | 15.1% |
| Next dividend pay date | 12 Jun 25 |
| Ex dividend date | 12 May 25 |
| Dividend per share | n/a |
| Payout ratio | 38% |
Recent dividend and buyback updates
Organon's (NYSE:OGN) Dividend Is Being Reduced To $0.02
May 04
Organon's (NYSE:OGN) Dividend Will Be $0.28
Feb 17Recent updates
Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) 30% Share Price Plunge
May 08Organon: Management Slashes Dividend - This Feels Disastrous
May 08Organon's (NYSE:OGN) Dividend Is Being Reduced To $0.02
May 04Organon (NYSE:OGN) Use Of Debt Could Be Considered Risky
Apr 28Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
Mar 24Why Organon Is A Top Pick For Income Investors
Mar 18Organon's (NYSE:OGN) Dividend Will Be $0.28
Feb 17Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Jan 17Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
Dec 13Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
Nov 13The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Nov 04Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Sep 19These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way
Sep 13
NEXPLANON And Biosimilars Drive Growth Amid Financial And Market Challenges
Aug 29 NEXPLANON's efficacy and expansion into new international markets are expected to drive significant revenue growth in women's health.Organon & Co.: Cheap With Caveats
Aug 22Organon (NYSE:OGN) Will Pay A Dividend Of $0.28
Aug 09Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price
Aug 07Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum
Jul 30Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year
May 29Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals
May 10Four Reasons Why Organon Stock Is A Good Buy
May 07Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings
Apr 21Organon Stock Is Still Worth A Look
Feb 24Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Feb 19Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
Feb 16Organon: What I'm Looking For In This 8% Yield In 2024
Jan 03High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued
Dec 19Organon: It's Darkest Before The Dawn
Nov 30Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace
Nov 07Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28
Nov 05Organon: The Federal Reserve Black Swan (Rating Upgrade)
Oct 046% Yield And Significantly Undervalued: A Closer Look At Organon
Sep 10Stability and Growth of Payments
Fetching dividends data
Stable Dividend: OGN has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: OGN has only been paying a dividend for 4 years, and since then payments have fallen.
Dividend Yield vs Market
| Organon Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (OGN) | 0.9% |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Pharmaceuticals) | 2.7% |
| Analyst forecast (OGN) (up to 3 years) | 0.9% |
Notable Dividend: OGN's dividend (0.89%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.54%).
High Dividend: OGN's dividend (0.89%) is low compared to the top 25% of dividend payers in the US market (4.66%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (38.5%), OGN's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (3.5%), OGN's dividend payments are thoroughly covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 06:40 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Organon & Co. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Navann Ty Dietschi | BNP Paribas Exane |
| Jason Matthew Gerberry | BofA Global Research |
| Sel Hardy | CFRA Equity Research |